Találati lista | Tudóstér

001-es BibID:	BIBFORM003761
Első szerző:	Nyolczas Noémi
Cím:	Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study : a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction / Nyolczas, N., Gyongyosi, M., Beran, G., Dettke, M., Graf, S., Sochor, H., Christ, G., Edes, I., Balogh, L., Krause, K. T., Jaquet, K., Kuck, K. H., Benedek, I., Hintea, T., Kiss, R., Preda, I., Kotevski, V., Pejkov, H., Dudek, D., Heba, G., Sylven, C., Charwat, S., Jacob, R., Maurer, G., Lang, I., Glogar, D.
Dátum:	2007
Megjegyzések:	Previous data suggest that bone marrow-derived stem cells (BM-SCs) decrease the infarct size and beneficially affect the postinfarction remodeling. METHODS: The Myocardial Stem Cell Administration After Acute Myocardial Infarction Study is a multicenter, prospective, randomized, single-blind clinical trial designed to compare the early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of BM-SCs to patients after acute myocardial infarction (AMI) with reopened infarct-related artery. The primary end points are the changes in resting myocardial perfusion defect size and left ventricular ejection fraction (gated single photon emission computed tomography [SPECT] scintigraphy) 3 months after BM-SCs therapy. The secondary end points relate to evaluation of (1) the safety and feasibility of the application modes, (2) the changes in left ventricular wall motion score index (transthoracic echocardiography), (3) myocardial voltage and segmental wall motion (NOGA mapping), (4) left ventricular end-diastolic and end-systolic volumes (contrast ventriculography), and (5) the clinical symptoms (Canadian Cardiovascular Society [CCS] anina score and New York Heart Association [NYHA] functional class) at follow-up. Three hundred sixty patients are randomly assigned into 1 of 4 groups: group A, early treatment (21-42 days after AMI) with intracoronary injection; group B, early treatment with combined application; group C, late treatment (3 months after AMI) with intracoronary delivery; and group D, late treatment with combined administration of BM-SCs. Besides the BM-SCs therapy, the standardized treatment of AMI is applied in all patients. CONCLUSIONS: The Myocardial Stem Cell Administration After Acute Myocardial Infarction Trial is the first randomized trial to investigate the effects of the combined (intramyocardial and intracoronary) and the intracoronary mode of delivery of BM-SCs therapy in the early and late periods after AMI.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Bone Marrow Cells Bone Marrow Transplantation Coronary Vessels Echocardiography Humans methods Multicenter Studies as Topic Myocardial Infarction Myocardium Perfusion Prospective Studies Research Design Single-Blind Method surgery therapy Time Factors
Megjelenés:	American Heart Journal. - 153 : 2 (2007), p. 212-217. -
További szerzők:	Gyöngyösi Mariann Beran, Gilbert Dettke, Markus Graf, Senta Sochor, Heinz Christ, Günther Édes István (1952-) (kardiológus) Balogh László (1976-) (kardiológus) Krause, Korff T. Jaquet, Kai Kuck, Karl Heinz Benedek Imre Hintea, Theodora Kiss Róbert Préda István Kotevski Vladimir Pejkov, Hristo Dudek, Darius Heba, Grzegorz Sylven, Christer Charwat, Silvia Jacob, Ronaldo Maurer, Gerald Lang, Irene Glogar, Dietmar
Internet cím:	elektronikus változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM003766
Első szerző:	Szűk Tibor (kardiológus)
Cím:	Effect of timing of clopidogrel administration on 30-day clinical outcomes : 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort / Szuk, T., Gyongyosi, M., Homorodi, N., Kristof, E., Kiraly, C., Edes, I. F., Facsko, A., Pavo, N., Sodeck, G., Strehblow, C., Farhan, S., Maurer, G., Glogar, D., Domanovits, H., Huber, K., Edes, I.
Dátum:	2007
Megjegyzések:	The aim of our prospective multicenter Clopidogrel Registry was to evaluate the efficacy and safety of a 300-mg loading dose of clopidogrel at the time of ad hoc stenting in patients with suspected coronary artery disease who were not pretreated with clopidogrel for any reason, and to compare the 30-day clinical event rates with the outcome of patients pretreated with a loading dose of clopidogrel 6 to 24 hours before stenting. METHODS: Between March 2002 and February 2004, 4160 consecutively included patients received a 300-mg loading dose of clopidogrel immediately after (group 1, n = 2679) or 6 to 24 hours before stenting (group 2, n = 1481). RESULTS: The primary end point (triple composite end point of acute myocardial infarction, all-cause death, and urgent repeat target vessel revascularization) at 30 days occurred in 4.74% versus 2.77% in groups 1 and 2, respectively (P = .002). The secondary end point events, the stent thrombosis, occurred significantly more frequently in group 1, with a trend toward increase in incidence of death, target vessel revascularization, or need for glycoprotein IIb/IIIa antagonists during percutaneous coronary intervention. Pretreatment with clopidogrel was associated with more major bleeding (secondary safety end point) (0.41% vs 1.35% in groups 1 and 2, respectively; P = .001). CONCLUSIONS: The results of our multicenter prospective Clopidogrel Registry demonstrate lower efficacy of a 300-mg loading dose of clopidogrel at the time of stenting compared with pretreatment 6 to 24 hours before percutaneous coronary intervention on the 30-day composite clinical end point in the large unselected patient cohort, which suggests the benefit of clopidogrel pretreatment in all incoming patients with suspected significant coronary artery disease scheduled for coronary angiography
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban administration &amp analogs &amp Combined Modality Therapy Coronary Angiography Coronary Artery Disease derivatives dosage Drug Administration Schedule drug therapy Female Humans Male methods Middle Aged Myocardial Infarction Myocardial Revascularization Platelet Aggregation Inhibitors Preoperative Care Prospective Studies Registries Stents surgery Ticlopidine Time Factors Treatment Outcome
Megjelenés:	American Heart Journal. - 153 : 2 (2007), p. 289-295. -
További szerzők:	Gyöngyösi Mariann Homoródi Nóra (1974-) (kardiológus) Kristóf Éva (1963-) (kardiológus) Király Csaba Édes István Ferenc (1980-) (kardiológus) Facskó Andrea (1953-) (szemész) Pavo, Noemi Sodeck, Gottfried Strehblow, Christoph Farhan, Serdar Maurer, Gerald Glogar, Dietmar Domanovits, Hans Huber, Kurt Édes István (1952-) (kardiológus)
Internet cím:	elektronikus változat DOI
Borító:
Saját polcon: